IDH1 and cholangiocarcinoma: With similar effects, among IDH inhibitors for gastrointestinal tumors, Ivosidenib is currently the only FDA-approved IDH inhibitor for treating previously treated locally advanced or metastatic CCA, targeting IDH1 mutation.